Alokda A, Soffar A, Yousef A, Ibrahim F, El-Sewedy T, Elmetwalli A
Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 40063241
DOI: 10.1007/s00210-025-03975-6.
Wan X, Yang L, Wu L, Lei J, Li J
J Cell Mol Med. 2025; 29(5):e70448.
PMID: 40032646
PMC: 11875785.
DOI: 10.1111/jcmm.70448.
Wu T, Long Q, Zeng L, Zhu J, Gao H, Deng Y
BMC Surg. 2025; 25(1):81.
PMID: 40016717
PMC: 11869450.
DOI: 10.1186/s12893-025-02802-2.
Liu G, Yu G, Yin D, Ma J
Sci Rep. 2025; 15(1):6794.
PMID: 40000809
PMC: 11861672.
DOI: 10.1038/s41598-025-91613-9.
Li J, Huang W, Kuang J, Zhou S, Li Y, Xia Y
PeerJ. 2025; 13:e18879.
PMID: 39995994
PMC: 11849516.
DOI: 10.7717/peerj.18879.
Mesenchymal stem cells modulate breast cancer progression through their secretome by downregulating ten-eleven translocation 1.
Motamed R, Jabbari K, Sheikhbahaei M, Ghazimoradi M, Ghodsi S, Jahangir M
Sci Rep. 2025; 15(1):6593.
PMID: 39994414
PMC: 11850621.
DOI: 10.1038/s41598-025-91314-3.
Construction of a novel disulfidptosis and cuproptosis-related lncRNA signature for predicting the clinical outcome and immune response in stomach adenocarcinoma.
Qu C, Yan X, Tang F, Li Y
Discov Oncol. 2025; 16(1):230.
PMID: 39992487
PMC: 11850681.
DOI: 10.1007/s12672-025-01969-7.
Theoretical perspectives and clinical applications of non-coding RNA in lung cancer metastasis: a systematic review.
Yang J, Luo Y, Yao Z, Wang Z, Jiang K
Discov Oncol. 2025; 16(1):169.
PMID: 39937377
PMC: 11822152.
DOI: 10.1007/s12672-025-01919-3.
An update on cancer stem cell survival pathways involved in chemoresistance in triple-negative breast cancer.
Jan A, Sofi S, Jan N, Mir M
Future Oncol. 2025; 21(6):715-735.
PMID: 39936282
PMC: 11881842.
DOI: 10.1080/14796694.2025.2461443.
TNBC response to paclitaxel phenocopies interferon response which reveals cell cycle-associated resistance mechanisms.
Calistri N, Liby T, Hu Z, Zhang H, Dane M, Gross S
Sci Rep. 2025; 15(1):4294.
PMID: 39905117
PMC: 11794704.
DOI: 10.1038/s41598-024-82218-9.
The novel piperine derivative MHJ-LN inhibits breast cancer by inducing apoptosis via p53 activation.
Ren H, Gao Q, Wang M, Zhang L, Wang S, Zhang X
Naunyn Schmiedebergs Arch Pharmacol. 2025; .
PMID: 39888362
DOI: 10.1007/s00210-025-03805-9.
Innovative Strategies in Oncology: Bacterial Membrane Vesicle-Based Drug Delivery Systems for Cancer Diagnosis and Therapy.
Li G, Pu S, You L, Gao Y, Zhong Y, Zhao H
Pharmaceutics. 2025; 17(1).
PMID: 39861706
PMC: 11768367.
DOI: 10.3390/pharmaceutics17010058.
Developing and validating a drug recommendation system based on tumor microenvironment and drug fingerprint.
Wang Y, Jin X, Qiu R, Ma B, Zhang S, Song X
Front Artif Intell. 2025; 7():1444127.
PMID: 39850847
PMC: 11755346.
DOI: 10.3389/frai.2024.1444127.
Dual ferroptosis induction in N2-TANs and TNBC cells via FTH1 targeting: A therapeutic strategy for triple-negative breast cancer.
Liu Y, Sun Q, Guo J, Yan L, Yan Y, Gong Y
Cell Rep Med. 2025; 6(1):101915.
PMID: 39809268
PMC: 11866498.
DOI: 10.1016/j.xcrm.2024.101915.
Hypoxic BMSC-derived exosomal miR-210-3p promotes progression of triple-negative breast cancer cells via NFIX-Wnt/β-catenin signaling axis.
Wang M, Zheng Y, Hao Q, Mao G, Dai Z, Zhai Z
J Transl Med. 2025; 23(1):39.
PMID: 39789572
PMC: 11720919.
DOI: 10.1186/s12967-024-05947-5.
WISP1 inhibition of YAP phosphorylation drives breast cancer growth and chemoresistance via TEAD4 activation.
Dong T, Liu L, You Y, Liu J, Wang F, Li S
Anticancer Drugs. 2025; 36(3):157-176.
PMID: 39774151
PMC: 11781553.
DOI: 10.1097/CAD.0000000000001687.
TPD52 as a Therapeutic Target Identified by Machine Learning Shapes the Immune Microenvironment in Breast Cancer.
Xia J, Zhou X
J Cell Mol Med. 2025; 29(1):e70333.
PMID: 39757112
PMC: 11702390.
DOI: 10.1111/jcmm.70333.
Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer.
Marei H, Bedair K, Hasan A, Al-Mansoori L, Caratelli S, Sconocchia G
Cancer Cell Int. 2025; 25(1):3.
PMID: 39755633
PMC: 11700463.
DOI: 10.1186/s12935-024-03615-8.
Machine learning-based selection of immune cell markers in osteosarcoma: prognostic determination and validation of CLK1 in disease progression.
Zhang N, Haizhen Z, Zhang R, Li X
Front Immunol. 2025; 15:1468875.
PMID: 39742274
PMC: 11685004.
DOI: 10.3389/fimmu.2024.1468875.
Tumor microenvironment and immunotherapy for triple-negative breast cancer.
Guo Z, Zhu Z, Lin X, Wang S, Wen Y, Wang L
Biomark Res. 2024; 12(1):166.
PMID: 39741315
PMC: 11689763.
DOI: 10.1186/s40364-024-00714-6.